Osiris Therapeutics Announces Scientific Manuscript Reporting Antimicrobial Properties of Cryopreserved Viable Amnion is Available Electronically in Peer-Reviewed Journal
January 13, 2017 17:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Jan. 13, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced today that a new peer-reviewed manuscript “Human cryopreserved viable amniotic membrane...
Osiris Provides Update Regarding NASDAQ Listing Matters
December 02, 2016 17:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Dec. 02, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the “Company”) today provided an update regarding the status of its compliance with the Listing Rules of...
Peer-reviewed Publication on the use of Grafix® in High-Risk Peripheral Arterial Disease Patients with Treatment Refractory Ulcerations Demonstrating Durable Wound Closure
November 22, 2016 17:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that a new peer-reviewed manuscript by physician and surgeon Jonathan Smedley, DPM, FACFAS,...
Osiris Provides Update Regarding NASDAQ Listing Matters
November 21, 2016 17:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the “Company”) today provided an update regarding the status of its compliance with the Listing Rules of...
Osiris Therapeutics, Inc. Reports Preliminary 2014 and 2015 Revenue and Anticipated 2016 Revenue
November 07, 2016 17:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care,...
Peer-reviewed Publication on the use of Grafix® Prime for Outpatient Management of Complex Wounds with Exposed Bone, Tendon, Muscle, Joint, and Hardware
October 31, 2016 16:30 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care,...
Grafix® Cost Comparative Manuscript Reporting Wound Care Cost Reduction is Available Electronically in a Peer-Reviewed Journal
October 26, 2016 16:30 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care,...
Osiris to Present Clinical and Scientific Studies at Desert Foot 2016
October 18, 2016 16:30 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing and marketing products to treat conditions...
Net Health and Osiris Therapeutics Announce the Broad Availability of Grafix® to Wound Care Patients Due to WoundExpert® EMR Integration
October 11, 2016 16:30 ET
|
Osiris Therapeutics, Inc.
PITTSBURGH, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Net Health, the leading provider of software solutions for specialized outpatient care, announced today that their partnership with Osiris...
Osiris Therapeutics Announces Appointment of Alberto Avendano, M.D. as Chief Medical Officer
October 06, 2016 17:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has appointed R. Alberto Avendano, M.D., as the Company’s Chief Medical Officer. ...